Background: Serum anti-heart autoantibodies (AHA) and anti-intercalated disk autoantibodies (AIDA) are autoimmune markers in myocarditis. In arrhythmogenic right ventricular cardiomyopathy (ARVC) myocarditis has been reported. To provide evidence for autoimmunity, we searched for AHA and AIDA in ARVC. Methods: We studied: 42 ARVC probands, 23 male, aged 42, interquartile range (IQR) 33;49, 20 from familial and 22 non-familial pedigrees; 37 clinically affected relatives (AR), 24 male aged 35, IQR 18;46; 96 healthy relatives (HR), 49 male, aged 27, IQR 17;45. Serum AHA and AIDA were tested by indirect immunofluorescence on human myocardium and skeletal muscle in 171 of the 175 ARVC individuals and in controls with: non-inflammatory cardiac disease (NICD) (n=160), ischemic heart failure (IHF) (n=141), normal blood donors (NBD) (n=270). Screening of five desmosomal genes was performed in probands; when a sequence variant was identified, cascade family screening followed, blind to immunological results. Results: AHA frequency was higher (36.8%) in probands, AR (37.8%) and HR (25%) than in NICD (1%), IHF (1%) or NBD (2.5%) (p=0.0001). AIDA frequency was higher in probands (8%, p=0.006), in AR (21.6%, p=0.00001) and in HR (14.6% p=0.00001) than in NICD (3.75%), IHF (2%) or NBD (0.3%). AHA positive status was associated with higher frequency of palpitation (p=0.004), ICD implantation (p=0.021), lower left ventricular ejection fraction (LVEF) (p=0.004), AIDA positive status with both lower RV and LVEF (p=0.027 and p=0.027 respectively). AHA and/or AIDA positive status in the proband and/or at least one of the respective relatives was more common in familial (17/20, 85%) than in sporadic (10/22, 45%) pedigrees (p=0.007). Conclusions: Presence of AHA and AIDA provides evidence of autoimmunity in the majority of familial and in almost half of sporadic ARVC. In probands and in AR these antibodies were associated with disease severity features; longitudinal studies are needed to clarify whether they may predict ARVC development in HR or if they be a result of manifest ARVC.

Background Identification of the culprit artery can be helpful in the management of inferior infarction with ST-segment elevation myocardial infarction. Some studies suggest that previously published algorithms intended to help identify the infarct-related artery are suboptimal. Our aim is to develop a better method to localise the culprit artery on the basis of the 12-lead ECG. Patients and methods We analysed the ECG and coronary angiograms of two different cohorts of patients with inferior ST-segment elevation myocardial infarction. Patients from the first cohort were labelled the derivative cohort (group A), whereas patients in the second cohort were labelled the validation cohort (group B). ST-segment elevation was measured in each lead, and a multiple logistic regression analysis was carried out to determine the best equation to predict the culprit artery. A derived algorithm was then applied to the validation cohort. Next, our algorithm was applied to the total cohort of both groups and compared with four different previously published algorithms. We analysed differences in sensitivity, specificity and area under the curve (AUC). Results We included 252 patients in the derivative group and 90 in the validation group. The multiple models analysis concluded that the best model should include five leads. This model was validated by internal bootstrapping with 1000 repetitions in group A and externally in group B. The resultant algorithm was as follows: (ST-elevation in III + aVF + V3) − (ST-elevation in II + V6) less than 0.75 mm means that the culprit artery is the left circumflex artery (Cx). If the result is at least 0.75, the culprit artery is the right coronary artery. The total group of both cohorts comprised 342 patients, aged 61.2 ± 12.4 years, of whom 19.6% were female and 80.4% were male. The Cx was the culprit artery in 67 (19.6%) patients. Our algorithm had a sensitivity of 72.3, a specificity of 80.9 and an AUC of 0.766. The AUC value was better compared with the other algorithms. Conclusion The best algorithm to localise the culprit artery includes ST-elevation in leads II and V6 related to Cx, and ST-elevation in leads III, aVF and V3 related to right coronary artery. Our algorithm has been validated internally and externally, and works better than other previously published algorithms.

No abstract

No abstract

Funding Acknowledgements Type of funding sources: None. Introduction Acute coronary syndrome (ACS) is one of the most common health problems in the world, and the leading cause of death. The goals of this study are to determine ACS incidence and the seasonal distribution of ocurrence (Spring/Summer/Autumn/Winter) as well as clinical outcomes per season. Methods Retrospective and observational analysis of consecutive patients hospitalized for ST-elevation myocardial infarction (STEMI) in the Critical Coronary Care Unit (CCCU) of a tertiary center with Mediterranean climate from July 2011 to September 2022. We analyzed the influence of the seasons on the incidence and characteristics of ACS. Results We enrolled a total of 1668 patients: 431 in Winter, 382 in Spring, 405 in Summer and 450 in Autumn, with the baseline characteristics summarized in Table 1. There were no differences in baseline characteristics among the 4 seasons, except for the higher prevalence of obesity in Autumn. There was no statistically significant difference in the incidence of STEMI among seasons, although numerically the highest incidence was recorded in Autumn. The occurrence of ACS was not different according to age or sex. ACS complications were not statistically different among seasons with similar incidence of ventricular arrythmias (VT, VF), invasive mechanical ventilation support, need for inotrope/vasopressor support or development of de-novo atrial fibrillation. In-hospital mortality is less frequent in Autumn, but the differences did not reach statistical significance. Conclusions In this Mediterranean climate cohort, STEMI incidence was higher in Autumn, although no differences in clinical profile or outcomes were found among seasons.